NCT03396185 - Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2023

Conditions

EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB

Interventions

DRUG

Icotinib

Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Science, Beijing